Chlamydia and Mycoplasma in Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
To test the association between anti-Chlamydia serum titers and anti-Mycoplasma antibodies with Acute Coronary Syndromes.

Detailed Description
-----------------
One hundred and twenty-six patients were divided into 4 groups: Acute Coronary Syndrome with ST-elevation, Non-ST-elevation, stable coronary artery disease, and individuals without coronary disease. Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured at baseline and after 6 months.

Official Title
-----------------
Prevalence of Chlamydia Pneumoniae and Mycoplasma Pneumoniae in Different Forms of Obstructive Coronary Artery Disease

Conditions
-----------------
Atherosclerosis, Coronary Artery Disease, Chlamydia Infections, Mycoplasma Infections

Intervention / Treatment
-----------------
* Other: blood sample analysis - mycoplasma and chlamydia antibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 yrs Males and females Agreed to sign the informed consent Exclusion Criteria: Refusal to sign the informed consent Follow-up not possible For the acute groups, time between the pain beginning and randomization >24 hours Active infections Use of antimicrobial agents within the last 30 days End-stage diseases with life expectancy <6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>ST-elevation acute myocardial infarction. | Other: blood sample analysis - mycoplasma and chlamydia antibodies<br>* Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).<br>|
| 2<br>high-risk unstable angina or non-ST-elevation myocardial infarction. | Other: blood sample analysis - mycoplasma and chlamydia antibodies<br>* Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).<br>|
| 3<br>known coronary artery disease, either asymptomatic or with stable angina. | Other: blood sample analysis - mycoplasma and chlamydia antibodies<br>* Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).<br>|
| 4<br>blood donors without known coronary artery disease. | Other: blood sample analysis - mycoplasma and chlamydia antibodies<br>* Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test the hypothesis that patients with acute coronary syndromes have higher levels of Chlamydia pneumonia and Mycoplasma pneumonia antibodies in comparison with patients with stable coronary artery disease or controls. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atherosclerosis, Coronary artery disease, Chlamydia pneumoniae, Mycoplasma pneumoniae